 Recently, Fludarabine plus 4 day dose of busulfan FluBu4 containing myeloablative regimen has been introduced successfully without increasing transplant-related mortality TRM. To improve transplant outcomes without increasing the risk of recurrence, Russell et al introduced 400cGy of TBI with antithymocyte ATG, 4.5mgKg into FluBu4 regimen with successful outcomes. 